UniXell Biotechnology, a leading company in the field of human PSC derived cell therapy for neurological diseases, was founded in 2021 with R&D center and GMP facility covering a total area of almost 4000 square meters.

UniXell has developed four highly innovative and integrated technology: Reprogramming technology, Stem cell differentiation, SISBAR pedigree tracing technology, High-precision gene editing.

These technological advantages enable UniXell to manufacture cell products of high purity and batch consistency, advancing toward the ultimate clinical goals of efficiency and safety.

The first pipeline product DA001 consists of mid-brain dopaminergic progenitor cells for the treatment of Parkinson's disease, is rapidly advancing into clinical stage testing.

With a team of highly experienced CMC, R&D and clinical experts, UniXell will continue to drive innovative stem cell strategies and endeavour to create a heathier future based on cutting edge science.